Promotion of lung tumors in mice. by Witschi, H P
Environmental Health Perspectives
Vol. 50, pp. 267-273, 1983
Promotion of Lung Tumors in Mice
by H. P. Witschi*
Several elements of two-stage carcinogenesis apply to the development of lung tumors in Strain A
or Swiss-Webster mice. At least three agents which have been identified as promoters in skin, uri-
nary bladder and liver will also enhance tumor formation in lung: phorbol, saccharin and butylated
hydroxytoluene (BHT). The antioxidant BHT acts in many respects like a typical promoting agent:
it is effective if animals are treated after exposure to an initiating agent, but not if they are treated
beforehand. Administration of BHT can be delayed up to 5 months after urethan treatment and still
enhance tumor formation. BHT enhances lung tumor formation regardless of its route of adminis-
tration (IP injection, gavage, or ingestion In the diet). The lowest dose of BHT required to produce
an effect has not yet been determined. In' at least one mouse strain, BHT also enhances tumor for-
mation in animals initiated with 3-methylcholanthrene or dimethylnitrosamine.
On the other hand, no evidence is available yet to show that BHT would enhance tumor develop-
ment in animals treated with subcarcinogenic doses of an initiating compound. Nor has it been pos-
sible to produce more tumors with BHT in mouse strains which have a low spontaneous tumor inci-
dence and respond poorly to urethan. The question has not been resolved whether BHT accelerates
growth of preformed tumors only or whether it induces the formation of more tumors. Nevertheless,
the data collected on the effects of BHT on mouse lung tumor development have broadened the con-
cept of two-stage carcinogenesis and complement the evidence for initiation- promotion available
for other epithelial tissues such as liver, colon, stomach, trachea, urinary bladder and mammary
gland.
Introduction
In 1972, Armuth and Berenblum (1) provided the
first evidence that the development of lung tumors
in mice might be enhanced by administration of a
promoting agent. When dimethylnitrosamine (DMN)
was injected into newborn AKR mice and the mice
treated subsequently with phorbol, both tumor inci-
dence and tumor multiplicity increased. When DMN
exposure was delayed until 10 days after birth, no
promoting effect of phorbol could be observed. The
authors concluded that phorbol, the well known pro-
moter of skin tumors in mice, might also act as a
systemic promoting agent in mouse lung provided
the initiating stimulus was given early after birth
(1). In 1977 it was reported that the development of
lung tumors in Strain A and Swiss- Webster mice
could be enhanced by repeated injections of the hin-
dered phenolic antioxidant butylated hydroxytolu-
ene (BHT) (2). A third chemical suspected to be a
promoting agent, saccharin (3), was found to influ-
ence tumor development in lung. Strain A mice
were pretreated for 1 week with four different com-
mercial preparations of the artificial sweetener,
*Biology Division, Oak Ridge National Laboratory, Oak
Ridge, TN 37830.
given one single injection of urethan (ethyl carba-
mate) and treated for another 16 weeks with saccha-
rin. When the animals were killed it was found that
the animals treated with both urethan and saccha-
rin had two to four times as many tumors per lung
as had animals treated with urethan alone (4).
There is thus evidence available to show that two
stage carcinogenesis may occur in mouse lung. Sev-
eral studies with BHT have now been done and the
data are discussed in some detail. The available in-
formation seems to suggest that the mouse
lung-BHT system can be taken as a valid example
of two-stage carcinogenesis.
Tumor Enhancement in Mouse
Lung
Temporal Relationship
The following experiments show that the devel-
opment of lung tumors in mice can be enhanced by
systemic administration of BHT. If certain mouse
strains, such as Strain A or Swiss Webster mice,
are treated with a variety of carcinogens, numerous
lung tumors develop in virtually all animals within 4
to 6 months (5). The number of tumors is propor-
tional to the amount of carcinogen administered.H. P. WITSCHI
One of the most effective agents is urethan. If Swiss
Webster mice or Strain A mice are injected with a
carcinogenic dose of urethan and subsequently
treated repeatedly with BHT, significantly more tu-
mors are found 4-6 months later compared to ap-
propriate controls. This was found to be true
whether BHT was injected intraperitoneally (2),
given by stomach tube (6) or offered to the animals
in the diet (7). Figure 1 shows the results of three
such experiments. In none of these experiments
was it found that BHT would influence tumor inci-
dence or tumor multiplicity if mice were treated
with NaCl instead of with urethan. This is in agree-
ment with other studies, where it was found that
BHT failed to produce lung tumors in mice (8).
On the other hand, pretreatment with BHT does
not influence tumor development. Swiss Webster
mice were given 13 weekly injections of BHT. One
week after the last BHT injection urethan was ad-
ministered, and the tumors per lung were counted 4
months later. No difference was found between ani-
mals exposed to BHT and given urethan and ani-
mals pretreated with corn oil before urethan injec-
tion (9). In a second experiment, animals were fed a
diet containing 0.75% BHT for 2 weeks and then in-
jected with a single dose of urethan. Again, no dif-
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FIGURE 1. Swiss-Webster or Strain A mice were given BHT
before or after a carcinogenic dose of urethan: (0) with
BHT; (Oi) control. Posttreatment with BHT enhanced
tumor development significantly, whereas pretreatment
had no effect. Asterisks (*) denote p<O.05. Data from
Witschi et al. (2, 6, 7, 9).
ference was found in animals pre-exposed to BHT
compared to the appropriate control groups (7).
Several experiments have now shown that BHT
effectively enhances tumor formation in mouse lung
provided the antioxidant treatment is begun after
administration of urethan. If the temporal sequence
of exposure is reversed, BHT has no effect. The sys-
tem meets therefore one important criterion usually
attributed to promoting agents: BHT is effective
only if given after initiation of tumor formation in
mouse lung by a carcinogen, but not if given prior
to the carcinogen. BHT alone is not carcinogenic.
A second question is whether delay of BHT expo-
sure up to several weeks after urethan still might
influence tumor development. First it was shown
that beginning BHT administration 6 weeks after
urethan still enhanced tumor formation (9). In a
more recent study, mice were given 1000 mg/kg of
urethan as an initiating dose (10). BHT treatments
(300 mg/kg IP, once a week for a total of four
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FIGURE 2. Effects of delay of BHT injection following one
single dose of urethan. Data from Witschi and Kehrer (10).
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weekly injections) were begun 1, 4, 7, 10, 13 or even
19 weeks later. Four months were allowed for tu-
mor expression between the first BHT injection and
killing of the animals. Accordingly, animals were
killed 16, 19, 22, 25, 28 or 35 weeks after urethan.
The data in Figure 2 show that in the BHT-treated
animals the number of tumors per lung is invariably
higher than in animals treated with corn oil. BHT
appears thus to fulfill a second criterion of a true
promoting agent.
Dose-Effect Relationships
In several experiments we examined the dose-
effect relationship between urethan and BHT. To
study the effects of various doses of BHT on lung
tumor development, mice treated with 1000 mg/kg
of urethan were given six injections of BHT ranging
from 50 mg to 300 mg/kg per injection. The lowest
dose of BHT, which amounted to a cumulative expo-
sure of 300 mg/kg of BHT was as effective in in-
creasing tumor multiplicity as was the highest dose
of BHT, which amounted to a cumulative dose of 1.8
g/kg of BHT (10). In a continuing feeding study, the
cumulative intake of BHT during an 8-week period
following urethan was estimated to be 35 to 40 g/kg.
In a second experiment, BHT-containing food was
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FIGURE 3. Dose-response to BHT: (A) 50 mg/kg, IP, six times;
(B) 300 mg/kg, IP, eight times; (C) 0.75% in food, eight
times; (D) 0.75% in food, 8 weeks. Data from Witschi and
Kehrer (10) and Witschi (7).
offered only once a week during 24 hr for consecu-
tive 8 weeks, and the cumulative intake of BHT was
estimated to be 5 g/kg (7). We found that BHT treat-
ment, regardless of total BHT intake, increased tu-
mor multiplicity 50 to 100% compared to controls
(Fig. 3). From these data it must be concluded that
so far there is no indication of a dose response to
BHT. The lowest dose of BHT needed to signifi-
cantly increase the number of urethan induced lung
tumors in mice has yet to be established. There is
one important proviso to this conclusion: one or
even two single injections of BHT have not been
found to enhance tumor multiplicity; the minimum
number of BHT injections required to have an ef-
fect is four (9). More recently we have found that a
diet containing 0.75% BHT is effective if given for 2
weeks only after urethan (Witschi, unpublished ob-
servations). Further experiments designed to define
the minimum time and dose required for BHT
intake in food necessary to enhance tumor develop-
ment are needed and have been initiated.
Criteria of a Promoting Agent BHT
Does Not Meet
While the evidence summarized so far strongly
suggests that BHT acts as a tumor promoter in
mouse lung, it should not be overlooked that BHT
fails to meet one criterion deemed to be important:
it does not enhance tumor formation following ad-
ministration of subcarcinogenic doses of urethan. In
a first experiment Swiss Webster mice were
treated with 50, 100, 250 or 1000 mg/kg of urethan,
given 13 weekly BHT injections and killed 4 months
later (9). Tumor multiplicity was only significantly
increased after 100 mg/kg of urethan or more (Fig.
4). The experiment was more recently repeated
using a slightly different protocol (Witschi, unpub-
lished observations). Strain A mice were injected
with 5, 25, 50 or 1000 mg/kg of urethan and placed
24 hr later for 8 weeks on a diet containing 0.75% of
BHT. The animals were killed 4 months after ure-
than, and we found that BHT increased tumor mul-
tiplicity only in animals treated with the highest
dose of the carcinogen (Fig. 4).
BHT is not effective in mouse strains which have
a low spontaneous incidence of lung tumors and are
resistant to the carcinogenic action of urethan. No
increase in tumor multiplicity or tumor incidence
was found in BALB/C, C57B1 and C3H mice treated
with urethan, even if animals were given repeated
injections of 300 mg/kg of BHT (9). These observa-
tions make one somewhat reluctant to label BHT a
typical promoting agent. However, no chemical to
be considered a promoter in such organs as liver,
stomach, urinary bladder or mammary gland seems
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FIGURE 4. Dose-response to urethan: (e) urethan
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urethan and then given IP injections of BHT
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to fulfill strictly all criteria originally dev
skin tumor-promoting agents (11). This m;
necessary to adopt perhaps less rigid cri
what constitutes a true two-stage carc
system. Two-stage carcinogenesis is an
toxicological concept and is an excellent e
document and to further study the role c
interactions when exposure to two or ml
is separated in time. To formulate underly
ples of toxicological interactions may be
portant than to judge only whether or not
lar experimental system fulfills the rigid
veloped originally for mouse skin only.
Mechanism of Action of BHO
The mechanisms by which BHT enhanc
mor formation in mice remain unknown.
nal rationale to study the effects of BHT
formation was as follows: in 1972 it was re
the first time that BHT was capable of
acute lung damage in mice (12). A few da
single dose of 400 mg/kg of BHT, lung lesi
tive of proliferative changes in the alveo
lium were found. Later studies showed t]
the first 24 hr after one single injectio
there is extensive and diffuse necrosis of
veolar epithelial cells. This is followed 2
later by proliferation and division of type
cells. Other pulmonary parenchymal cells
terstitial cells and capillary endothelial dii
days after BHT injections (13, 14).
Morphologic observations together with data on
accumulation and disappearance of BHT from the
* lung (15) seemed to make it unlikely that BHT
would act directly on type II pneumocytes, the cells
believed to be the precursor cells of lung tumors in
mice. Rather, it was assumed that repeated prolifer-
ation of type II cells, secondary to BHT-induced
type I cell necrosis, would be the mechanism of tu-
mor promotion in lung. This assumption was based
on the suggestion that in mouse skin all promoting
agents are chemicals capable to elicit gene activation
=0 and cell proliferation (16). It was therefore logical to
e? link BHT-induced type II cell proliferation and en-
hancement of tumorigenesis. However, some more
months recent experiments have shown that it is possible to
In enhance tumor formation in mouse lung by BHT
even in the absence of overall cell proliferation. On
i+ BHT; (o) the other hand, no enhancement of tumor formation
as doses of can be produced by several agents which do pro-
(9) (left) or duce cell proliferation in lung. The evidence is as fol-
ublished ob-
ter urethan. lows. Initially it was assumed that each weekly in- jection of BHT would be followed by a burst of cell
proliferation in mouse lung. Newer data have shown
that this assumption is not correct. While substan-
reloped for tial cell proliferation is readily demonstrated on
ay make it days 2 to 5 after one single injection of BHT,
teria as to subsequent BHT injections given at weekly inter-
inogenesis vals fail to produce further cell divisions. This has important been demonstrated in twoindependent experiments ixample to with the use of autoradiography (Witschi, unpub- xfchemical lished observations) or biochemical techniques (17)
ore agents to assess cell proliferation. Since more than one in- oing princi- jection of BHT is required to enhance tumor forma-
inmore im- tion, it must be assumed that cell proliferation is
ta particu- not a key element to explain the effects of BHT.
criteria de- Furthermore we have found that no cell prolifera-
tion is detectable in mouse lung if animals are
treated shortly before or after BHT with SKF 525A
T (18) or are treated with low doses of BHT (50
mg/kg). Nevertheless, if animals are initiated with
es lung tu- urethan and then given repeated small doses of
The origi- BHT or given a combination of BHT and SKF 525A,
on tumor tumor multiplicity is greater than in controls (10).
,ported for BHT thus has an effect whether it produces cell
producing proliferation in mouse lung or not (10).
tys after a On the other hand, two agents which are known
ons indica- to produce a burst of cell proliferation in lung will
lar epithe- not influence tumor development. If mice are ex-
hat within posed after urethan repeatedly to 100% oxygen,
in of BHT tumor formation is not enhanced (10). Repeated in-
type I al- traperitoneal injections of methylcyclopentadienyl
to 4 days maganese tricarbonyl (MMT) are also without effect
II alveolar on tumor development (5). There exists a discrep-
such as in- ancy between cell proliferation in lung and tumor
vide 5 to 6 promotion.
Finally, it is necessary to consider whether the
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antioxidant properties of BHT are related to its tu-
mor enhancing effects. At the moment this is not a
likely possibility. The structural analog of BHT, bu-
tylated hydroxyanisole (BHA) does not promote tu-
mor formation whether it is injected intraperitone-
ally or administered to urethan treated animals in
the diet (7, 10). Vitamin E and ethoxyquin are also
without any effect (Fig. 5).
The precise mechanism of action of BHT in
mouse lung remains to be established. Some in vitro
data obtained with BHT might provide clues for the
design of mechanistic experiments. BHT is cyto-
toxic and may cause swelling and lysis of cells and
depression of metabolic activities such as RNA and
protein synthesis (19). In phytohemagglutinin-stim-
ulated lymphocytes a mixture of BHT and Tween-80
produces a marked uncoiling of chromosomes as
well as extensive cell membrane damage (20, 21).
BHT perturbs artificial membrane systems (22) and
inactivates lipid-containing mammalian and bacter-
ial viruses (23). There is thus evidence to suggest
that BHT interferes with the structural and func-
tional integrity of membrane systems. How exactly
these mechanisms relate to enhancement of tumor
formation remains to be seen. However, detailed
studies at a mechanistic level might not be easily ac-
complished. The lung is a very heterogenous organ
composed of many different cell types and isolation
of pure cell populations can present technical diffi-
culties. Moreover, the cells of origin of lung tumors
in mice are not known with certainty yet. In Strain
A mice, more than 80% of lung tumors seem to
develop from type II alveolar epithelial cells. In
Swiss Webster mice it appears that most lung tu-
mors develop from the nonciliated cells lining the
small airways, the so called Clara cells (Haschek and
Witschi, unpublished observations). Since we have
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found a similar response to BHT in both Strain A
and Swiss Webster mice we must assume for the
moment that BHT somehow enhances tumor forma-
tion regardless of the cells of origin of lung tumors.
An unresolved problem remains whether BHT in-
creases the actual number of tumors formed or sim-
ply accelerates tumor growth. In all experiments tu-
mors were counted on the lung surface. If more tu-
mors are found in animals 4-6 months after BHT, it
could be that a surface count was not detecting tu-
mors lying deep in the lung parenchyma. It might
not be possible to conclude whether BHT simply ac-
celerated growth of preformed tumors. To answer
this question we recently compared in several ex-
periments the number of tumors visible on the lung
surface to the number of all tumors visible after
clearing the lung. The ratio between the two counts
was practically 1:1 (7). Surface counting reflects
therefore accurately the number of tumors visible
to the naked eye or visible under a dissecting micro-
scope. It was concluded that BHT produced within 4
months more visible tumors. On the other hand, we
have found that the difference between tumor mul-
tiplicity in BHT-treated animals and controls is
greater 4 months after urethan than it is 6 or even
9 months after urethan. (Fig. 6). Therefore, we
cannot exclude with confidence the possibility that
BHT might accelerate, early after urethan, the
growth of clusters of transformed cells into visible
tumors. This problem remains to be studied further.
In most experiments a dose of urethan was given
designed to produce a 90 to 100% tumor incidence
in both control and BHT treated animals. This ex-
perimental design allows to detect whether BHT
treatment increases tumor multiplicity, but does
not allow to determine whether BHT affects tumor
incidence. In animals treated with other initiators
such as 3-methylcholanthrene, dimethylnitrosamine
or with lower doses of urethan or with no carcino-
gen at all, a significantly increased number of
tumor-bearing animals was occasionally observed
following BHT treatment, but not regularly. In
conclusion, while it is certain that BHT increases
the number of tumors per lung, it is not yet clear
whether this is caused by accelerated tumor growth
or by increased formation of tumors.
Effects of Different Initiators
I XI XI XT The data base available to document that BHT
LLII/ / / Xenhances tumor formation in mice treated with
IBHT BHA Ethoxyquin BHT BHA Vit.E other carcinogens than urethan is limited. A feeding
Diet i.p
A
study provided some suggestive but not conclusive DieEffectsofBHTBHA e y inorvitaminE evidence that BHT might enhance lung tumor for- 5. Effects of BHT, BHA, ethoxyquin or vitamin E on mainnaialprteedwhdehyiro tumor development in lung following urethan. White mation in anmals pretreated with diethylnitro-
denote controls. Data from Witschi et al. (5, 7). samine (24). In Swiss Webster mice given dimethyl-
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FIGURE 6. Strain A mice were injected with 1000 mg/kg of
urethan and given eight weekly IP injections of 300 mg/kg
of BHT: (.) urethan x 300 mg/kg BHT, eight times; (o)
urethan x oil. The animals were killed 4, 6, or 9 months
after urethan. Asterisks (*) denote p<0.05 (Witschi, unpub-
lished observations).
nitrosamine or 3-methylcholanthrene, BHT treat-
ment had no effect (10). However, in Strain A mice
given the same carcinogens, BHT was capable of en-
hancing tumor formation (5). The reasons for these
conflicting observations are not clear. In Swiss
Webster mice, both methylcholanthrene and di-
methylnitrosamine might have produced not
enough tumors in order to show the effect of BHT.
However the same reasoning cannot be applied to
understand the data obtained in Strain A mice: in
Strain A mice tumor formation after dimethylnitro-
samine was significantly increased even if the dose
of dimethylnitrosamine used produced only a lim-
ited number of tumors per lung. Further studies are
needed to establish unambiguously whether BHT
enhances tumor formation in mouse lung following
administration of other carcinogens than urethan.
Conclusions
Data reviewed show that BHT fulfills many cri-
teria of a typical promoting agent: it effectively en-
hances tumor formation in animals exposed to BHT
after being injected with urethan but not if they are
treated with BHT before urethan. Administration
of BHT can be delayed for several months after ure-
than treatment and still can enhance tumor for-
mation. Route of administration does not play a role
and more tumors compared to controls develop
whether BHT is given by intraperitoneal injection,
oral gavage or whether the animals eat it in the
diet. The lowest effective dose of BHT has not yet
been determined. On the other hand, it has not been
possible yet to show that BHT enhances tumor de-
velopment in animals exposed to subcarcinogenic
doses of an initiating compound. Evidence to show
that BHT enhances tumor formation following ad-
ministration of other carcinogens such as nitrosa-
mines or polycyclic hydrocarbons is positive in one
mouse strain and negative in another. Whether
BHT accelerates growth of preformed tumors or
whether it induces formation of more tumors
remains to be reexamined. BHT does not fulfill all
the criteria usually set for promoters in the skin tu-
mor model.
However it must be mentioned that BHT acts as
a promoting agent in two other systems. In one
study, rats were treated with acetylaminofluorene
and placed on a diet containing 0.5% BHT. BHT
substantially enhanced tumor formation in the liver
(25).
In an in vitro system, BHT inhibits metabolic co-
operation between cells, a feature commonly attri-
buted to promoting agents (26).
The findings that BHT acts like a promoting
agent in three different experimental systems may
require a reevaluation of the safety of BHT as a
food additive.
In conclusion, there is now good experimental evi-
dence to show that several elements of two-stage
carcinogenesis apply to the development of lung tu-
mors in mice. So far, three agents believed to be
promoters in other tissues enhance tumor formation
in lung: phorbol, a classical skin promoter; sac-
charin, which is an accepted promoting agent for
bladder tumor; and BHT, which has been found in
at least one study to enhance tumor formation in
liver. The mouse lung tumor system has been
suggested as a screening assay for detection of
complete carcinogens (27). It should be considered
whether the use of the mouse lung assay could be
expanded by using BHT and possibly other agents
as promoters. The assay could then serve to detect
complete carcinogens as well as initiators, cocar-
cinogens, promoters and possibly even copromoters.
This research was sponsored by the Office of Health and
Environmental Research, U.S. Department of Energy, under
contract W-7405-eng-26 with the Union Carbide Corporation.
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